Clinical Trials
27 trialsNCT07606599 2026-05-26
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07582315 2026-05-22
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT05489211 2026-03-19
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT07437287 2026-02-27
CROCOBIL
UNICANCER
Phase 2/3 Not yet recruiting
NCT03785873 2026-02-13
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT06219941 2026-02-12
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
Phase 2 Recruiting
NCT04005339 2026-01-26
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Georgetown University
Phase 2 Active not recruiting
NCT06428409 2026-01-22
MK-9999-02A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05482893 2025-11-04
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phanes Therapeutics
Phase 1/2 Recruiting
NCT03044587 2025-10-01
NIFE
AIO-Studien-gGmbH
Phase 2 Completed
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT03314935 2025-08-12
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT07025174 2025-06-17
SAIB
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06662877 2024-10-29
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
Sun Yat-sen University
Phase 2/3 Not yet recruiting
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05116891 2023-07-03
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
Phase 1/2 Completed
NCT03524508 2022-08-24
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
Asan Medical Center
Phase 2 Completed
NCT03110510 2022-06-15
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
Samsung Medical Center
Phase 2 Withdrawn
NCT04480190 2022-04-20
Neoadjuvant Therapy in Biliary Adenocarcinoma
University of Cincinnati
Phase 1 Withdrawn
NCT03778593 2021-02-04
FOLFIRINOX for 2nd-line Treatment of BTC
Dong-A University Hospital
Phase 2 Completed
NCT01926236 2020-01-28
ABC06
The Christie NHS Foundation Trust
Phase 3 Completed
NCT03668418 2018-09-12
xenoZ
University of Pisa
Unknown
NCT01572324 2017-01-04
Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas
Peking University
Phase 2 Completed
NCT01661114 2016-10-19
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01127555 2013-10-08
Salvage mFOLFOX in BTC After Failure of Gemcitabine
Chung-Ang University
Phase 2 Completed
NCT01494363 2011-12-19
Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
Soon Chun Hyang University
Phase 2 Unknown
NCT00090025 2009-01-14
XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors
Helsinn Healthcare SA
Phase 3 Terminated